These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from March 28 through April 3, 2024. Source: VerityData
Increases in Holdings
ARS Pharmaceuticals RA Capital Management increased its stake in the biopharmaceutical company to 10,860,977 shares. RA Capital Management did so through the purchase of 1,401,299 ARS Pharmaceuticals shares from March 25 through March 27 at per share prices ranging from $8.89 to $10.
Following the purchases, RA Capital Management now owns 11.3% of ARS Pharmaceuticals' outstanding stock. Shares have surged more than 70% so far this year.
Decreases in Holdings
Nuvalent Bain Capital Investors reduced its stake in the oncology-focused pharmaceutical company to 2,697,267 shares. Bain Capital Investors did so through the sale of 880,000 Nuvalent shares on March 27 at a weighted average price of $72.77 each.
Following the sale, Bain Capital Investors owns approximately 4.6% of Nuvalent's outstanding shares, placing it below the 5% threshold that would require it to report any further Nuvalent stock sales. Shares of Nuvalent have been about flat so far this year.
Vera Therapeutics Sofinnova Venture Partners X lowered its stake in the clinical-stage biotechnology company to 2,793,987 shares. Sofinnova Venture Partners did so through the sale of 834,459 Vera Therapeutics shares from March 21 through March 25 at per share prices ranging from $40.50 to $46.94. In connection with a follow-on offering in January, Sofinnova purchased 161,290 Vera Therapeutics shares for $31 apiece.
Following the recent sale, Sofinnova continues to own 5.3% of Vera Therapeutics' outstanding stock. Shares have rocketed more than 130% year to date.
Phathom Pharmaceuticals Takeda Pharmaceutical cut its stake in the clinical-stage biopharmaceutical company to 3,153,217 shares. Takeda Pharmaceutical sold 602,366 Phathom Pharmaceutical shares from Feb. 29 through March 28 at prices ranging from $10 to $11.40 apiece. Takeda Pharmaceuticals last sold 3,703,703 shares in January to Medicxi IV through a privately negotiated sale at $8.10 apiece.
Following the sales, Takeda Pharmaceutical owns roughly 5.4% of Phathom Pharmaceuticals' outstanding stock. Shares have gained about 18% year to date.
KalVista Pharmaceuticals TCG Crossover GP I slashed its stake in the pharmaceutical company to 1,345,826 shares. TCG Crossover did so through the sale of 1,355,014 KalVista Pharmaceuticals shares on March 28 at an average price of $11 apiece. TCG Crossover has been lowering its stake in KalVista Pharmaceuticals since February, when it sold 877,125 shares at prices ranging from $12.85 to $16.22 each.
Following the sales, TCG Crossover now owns 3.2% of KalVista Pharmaceuticals' outstanding stock, below the 5% threshold that would require it to report further KalVista stock sales. Shares have lost about 8% so far this year.
Email: editors@barrons.com
This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
April 05, 2024 18:30 ET (22:30 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Comments